Company intelligence / Profile preview

Synimmune

Tübingen, Baden-Württemberg, Germanypitchbook.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Synimmune developed a clinical-stage, Fc-enhanced monoclonal antibody targeting FLT3 (FLYSYN) for acute myeloid leukemia. The Phase 1 trial in AML patients at high risk of relapse showed the therapy was safe, well tolerated, and demonstrated early signs of efficacy in 31 patients. The company also had preclinical or early-stage assets targeting CD19 and CD133.

Therapeutic areas: HematologyOncology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Drug pipeline

1 asset

GTL101

Pre-clinical

Indications: Acute myeloid leukemia

Beyond the preview

Go deeper on Synimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synimmune.

Explore the full profile